BRIEF—Sandoz launches Symjepi in the USA

US-based generics firm Sandoz, a Novartis division, has launched Symjepi (epinephrine) for the emergency treatment of allergic reactions in the USA. The firm says the product will be an “affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.”

President Carol Lynch said: “The Symjepi device is small in size and fits into the palm of your hand, with the goal of a simple-to-use application and intuitive, user-friendly design.”

“At Sandoz, we strive to reimagine medicine to offer the best care we can in all we do, and having heard from patients, caregivers and healthcare professionals about their eagerness for a new product, we are proud to be a part of the solution to a critical need in the US.”